Outcome measures were selected and prioritized based on guidelines and stakeholder input. They will be collected at baseline, at 3, 6, 9 and 12 months. Only baseline and 12 months post-entry data collection will be conducted in person; the 3, 6, and 9-month data collection will occur online or by phone to minimize burden. Pain severity and function, as assessed by standard, validated survey measures, will serve as primary (Aim 1), and quality of life and opioid dose (morphine-equivalent mg/day) as secondary (Aim 2) outcomes. Severity of negative affect (depression, anxiety) and opioid misuse behaviors, also measured by validated surveys, are the main hypothesized predictors of treatment success (Aim 3). The repeated measures intention-to-treat outcome analysis will compare the change in primary and secondary outcomes over the 12 month period and across the two groups. To determine prognostic factors of treatment effect, a linear mixed model analysis will be performed for Aim 1 and Aim 2 outcomes, adjusting for potential confounders, study site and a random intercept for subject.